Based on other studies showing that the two resveratrol isomers even have opposing effects with respect to PARP1 activation, and the finding that methoxylated cis-derivatives are superior to the corresponding trans-derivatives in their antitumor efficacy, it becomes clear that not only trans-resveratrol but also cis-resveratrol represents an extremely interesting lead structure for the development of drugs for the prevention and therapy of tumor diseases with particularly unfavorable prognosis. Here, PARP1 is linked to neoplasm.